GlassScriptPhysician profile
John A Depalma
NPI 1407054471
$6,504.02
in general payments reported to CMS, 2019-2025
35 companies · $965 in 2025
The $965 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $630 · 2021: $1,343 · 2022: $617 · 2023: $724 · 2024: $968 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.28 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,886.82 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $816.56 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $379.63 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $234.86 | 2019-2025 | Voyxact, Jynarque |
| Opko Pharmaceuticals, LLC | $225.97 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $220.50 | 2022-2025 | Lupkynis |
| Amgen INC. | $216.95 | 2024-2025 | Krystexxa, Tavneos |
| W. L. Gore & Associates, INC. | $215.25 | 2019-2021 | |
| Glaxosmithkline, LLC. | $208.01 | 2022-2025 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $201.46 | 2019-2025 | |
| Ardelyx, INC. | $163.21 | 2024-2025 | Ibsrela |
| Davol INC. | $140.41 | 2021 | |
| Novo Nordisk INC | $138.74 | 2024-2025 | Ozempic, Wegovy |
| Horizon Therapeutics Plc | $135.10 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $133.65 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $131.20 | 2020-2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $129.72 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $118.70 | 2019-2022 | |
| Infobionic, INC | $99.18 | 2020 | |
| Daiichi Sankyo INC. | $93.00 | 2019-2023 | Injectafer |
| Akebia Therapeutics INC | $90.96 | 2019-2025 | Vafseo, Auryxia |
| Boston Scientific Corporation | $88.11 | 2022 | |
| Calliditas Therapeutics US INC. | $61.06 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $58.69 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.61 | 2020-2024 | Gattex |
| Lundbeck LLC | $52.73 | 2019 | |
| Shire North American Group INC | $37.86 | 2019 | |
| Bard Peripheral Vascular, INC. | $30.10 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.15 | 2019 | |
| Amarin Pharma, INC. | $23.99 | 2019-2020 | |
| Nxstage Medical, INC. | $22.00 | 2022 | |
| Scpharmaceuticals INC. | $21.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.20 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $13.76 | 2025 | |
| Baxter Healthcare | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Depalma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.